Tvardi Therapeutics, Inc. — Form 8-K
Filed July 17, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Tvardi Therapeutics registered a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC, dated May 1, 2026, to issue up to 9,689,765 shares of common stock with aggregate offering price of $9,689,765 (implying ~$1.00/share). The offering is governed by Form S-3 registration statement (File No. 333-295496) and prospectus supplement dated July 17, 2026. Cooley LLP provided legal opinion that shares, when issued per the agreement and prospectus, will be validly issued, fully paid, and nonassessable.
Why this rating
At-the-market offering of ~4.7% of current market cap ($9.7M vs. $207.2M). Dilutive but routine capital raise for development-stage biotech; material in absolute terms but manageable relative to company size.
See more from July 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.